Diabetes mellitus is among the most common disorder in developed and developing countries, and the disease is increasing rapidly in most parts of the world. It has been estimated that up to one-third of patients with diabetes mellitus use some form of complementary and alternative medicine. The aim of the present study was to evaluate synergistic antidiabetic and antihyperlipidaemic effects of Momordica charantia fruit juice along with Glibenclamide (lower dose) on glucose tolerance and lipid profile in streptozotocin induced diabetic rat. The Momordica charantia fruit juice (MCFJ) were prepared and different combination of MCFJ and Glibenclamide was evaluated for antidiabetic activity in experimental animals. The administration of MCFJ along with Glibenclamide significantly decreased the blood glucose levels compared to control diabetic rats. The MCFJ along with Glibenclamide significantly lowered the elevated total cholesterol, triglycerides (TGL), total protein and low density lipoprotein (LDL) level while increased the high density lipoprotein (HDL) indicates the antihyperlipidaemic activity. The findings demonstrated the MCFJ enhanced antidiabetic and antihyperlipidaemic activity of Glibenclamide and produced higher protective effect from diabetes.
Introduction
Diabetes mellitus (DM) is a severe medical issue being the third most noteworthy reason for death everywhere throughout the world, and if not treated, it is in charge of numerous complications influencing different organs in the body. The chronic hyperglycemia of diabetes is accompanying with long term damage, dysfunction, and failure of different organs 1 .
Internationally, starting at 2010, an expected 285 million individuals had diabetes, with type 2 making up about 90% of the cases. The World Health Organization measures an increase from 171 million out of 2000 to 366 million of every 2030 2 .
Roughly 70% of this development is anticipated to occur in the developing world and will progressively influence individuals matured more youthful than 65 years who are still in the productive stages of their life cycle.
Type 2 Diabetes mellitus (T2DM), the most well-known type of diabetes, is portrayed by hindered insulin sensitivity and secretion. Unlike Type 1 Diabetes mellitus (T1DM), people with T2DM hold a assured production of insulin although inadequate to keep the blood glucose inside ordinary range. The significant hazard factors which impact the developing T2DM are obesity and a family history of the disease 3 . In type 2 diabetes, the body can deliver insulin however either this isn't adequate or the body can't react to its belongings, prompting a development of glucose in the blood. Numerous individuals with type 2 diabetes stay ignorant of their sickness for a long time because symptoms may take a very long time to show up or be perceived. 
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The Glibenclamide is widely used as antidiabetic agent, but associated with side effects. The side effects of Glibenclamide can be reduce by decreasing its dose. Hence, the present study was planned to administer the Momordica charantia juice and Glibenclamide together to STZ induced diabetic rats, and investigate their antidiabetic and antihyperlipidaemic efficacy.
Material and Methods

Plant material
The fresh fruits of Momordica charantia were collected and authenticated by an authority in plant taxonomy.
Juice preparation
Momordica charantia fruits (MCF) were washed thoroughly, and fresh juice was prepared on a juicer eliminating seeds. It was centrifuged at 1000 rpm on a tabletop refrigerated centrifuge for 10 min at 4°C. The clear supernatant was considered as 100%
Momordica charantia fruit juice (MCFJ) which was stored at 4°C for further use 10 .
Animals
The animals were carried for experiment from the authorised animal house of Bhopal Nobles College of Pharmacy, Undaipur (RJ), India. All Wistar almino rats were healthy and 150 gm to 220 gm of body weight. The animals were kept in air conditioning environment and temperature was maintained to 25±2 0 C with conventional laboratory food and fresh drinking water. The bedding of animals was changed every 3 rd day.
Induction of diabetes
Hyperglycemia was induced by injecting single intraperitoneal injection of streptozotocin (STZ) at a dose of 60 mg/kg, 15 minutes after i.p. administration of 120 mg/kg of nicotinamide.
The animals were kept under observation. After 72 hrs, the animals were tested for glucosuria using Diastex strips. Seven days after the STZ injection, rats with fasting blood glucose levels greater than 125 mg/dL were considered diabetic.
Treatment Protocol
Diabetic animals were randomly assigned into the following groups of six animals each and treated as follows.
Group I served as normal rats, administered drinking water daily for 28 days Group II had diabetic control rats, administered drinking water daily for 28 days Group III rats were administered standard drug Glibenclamide (50 mg/kg) daily for 28 days Group IV rats were administered MCFJ (5 ml/kg body weight) + Glibenclamide (0.5 mg/kg) daily for 28 days Group V rats were administered MCFJ (10 ml/kg body weight) + Glibenclamide (0.5 mg/kg) daily for 28 days Group VI rats were administered MCFJ (15 ml/kg body weight) + Glibenclamide (0.5 mg/kg) daily for 28 days The fasting glucose levels were determined on days 7 th , 14 th , 21 st and 28 th after juice administration.
Estimation of biochemical parameters
The biochemical parameters were determined on day 28 after the animals were sacrificed by cervical dislocation. Total cholesterol, triglycerides (TGL), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total protein were determined by using an auto-analyzer 11-14 .
Statistical analysis
The results are expressed as mean ± SEM of six independent experiments. Statistical significance between the groups was evaluated by one-way analysis of variance (ANOVA) followed by Dunet's test. A P < 0.05 value was considered as statistically significant.
Results and Discussions
Antidiabetic effect of MCFJ
The existence of high fasting glucose level demonstrated the stimulation of diabetes in rats. The antidiabetic activity of MCFJ along with Glibenclamide on serum glucose levels of normal and Streptozotocin-induced rats are exhibited in table 1. The streptozotocin treated rats indicates significant increase in serum glucose level on 7 th , 14 th , 21 st and 28 th day compared to normal group rats. The administration of MCFJ at different doses along with Glibenclamide to rats leads to significant decrease in in blood glucose level. The findings exhibited that MCFJ (15 ml/kg) along with Glibenclamide (0.5 mg/kg) produces more potent antidiabetic activity compared to other groups. The glucose level of group IV animals were nearer to standard group. This indicates that the administration of MCFJ and Glibenclamide produces synergistic effect and at lower dose of Glibenclamide have potent antidiabetic activity similar to higher dose of Glibenclamide. 
Antihyperlipidaemic effect of MCFJ
The management of lipid profiles in different groups of rats is exhibited in table 2. The significant increase in TGL, total cholesterol, LDL and total protein while decrease in HDL observed in diabetic control rats compared with normal rats. The The antidiabetic activity of MCFJ along with Glibenclamide at lower doses were similar to higher doses of Glibenclamide antidiabetic activity. This indicates that the addition of MCFJ increased the potency of Glibenclamide. Further the lower doses of Glibenclamide can produced minimum side effects to body.
Conclusion
The animals treated with the MCFJ along with Glibenclamide at lower doses exhibited synergistic antidiabetic activity. The potency of antidiabetic efficacy of Glibenclamide enhanced, and lower doses of Glibenclamide along with MCFJ produces similar antidiabetic activity produced by higher dose of Glibenclamide.
In future studies will be conduct to elucidate the proper mechanism of action of antidiabetic activity impart by MCFJ along with Glibenclamide.
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